Bluebird Bio

LentiGlobin gene therapy for sickle cell on course for filing, says bluebird
LentiGlobin gene therapy for sickle cell on course for filing, says bluebird
Pharmaforum
LentiGlobin
Bluebird Bio
sickle cell disease
Flag link:
Myeloma cell therapies, now in pharma hands, move into spotlight
Myeloma cell therapies, now in pharma hands, move into spotlight
Biopharma Dive
ASH2019
cell therapies
Multiple Myeloma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
Flag link:
The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
Yahoo/Benzinga
ASH2019
Roche
Bristol-Myers Squibb
Acadia Pharmaceuticals
Biogen
Cassava Sciences
Alector
GW Pharma
Magenta Therapeutics
Fortress Biotech
Mustang Bio
Bluebird Bio
Flag link:
Pfizer, Novartis lead $2 billion spending spree on gene therapy production
Pfizer, Novartis lead $2 billion spending spree on gene therapy production
Reuters
gene therapy
drug manufacturing
Pfizer
Novartis
Bluebird Bio
PTC Therapeutics
Krystal Biotech
Flag link:
Bluebird gets European green light for gene therapy production
Bluebird gets European green light for gene therapy production
Biopharma Dive
Bluebird Bio
gene therapy
Europe
Zynteglo
Flag link:
Why Novo Nordisk should buy Uniqure
Why Novo Nordisk should buy Uniqure
EP Vantage
Novo Nordisk
gene editing
hemophilia
uniQure
Bluebird Bio
Flag link:
Novo taps bluebird bio for gene-editing tech
Novo taps bluebird bio for gene-editing tech
Fierce Biotech
Novo Nordisk
Bluebird Bio
R&D
gene editing
hemophilia
Flag link:
bluebird presents long-term data from CALD gene therapy
bluebird presents long-term data from CALD gene therapy
Pharmaforum
Bluebird Bio
gene therapy
cALD
Lenti-D
Flag link:
The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck
The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck
Yahoo/Benzinga
Merck
Pifeltro
FDA
Delstrigo
Novo Nordisk
oral semaglutide
Kodiak Sciences
MeiraGTx Holdings
IPOs
Exagen
IGM Biosciences
Arrowhead Pharmaceuticals
Lexicon Pharmaceuticals
Bluebird Bio
vTv Therapeutics
Flag link:
bluebird bio Prepares for Launch
bluebird bio Prepares for Launch
Motley Fool
Bluebird Bio
Zynteglo
beta-thalassemia
drug launches
Flag link:
Bluebird Bio (BLUE) Reports Q2 Loss, Tops Revenue Estimates
Bluebird Bio (BLUE) Reports Q2 Loss, Tops Revenue Estimates
Yahoo/Zacks.com
Bluebird Bio
earnings
Flag link:
Where Will bluebird bio Be in 1 Year?
Where Will bluebird bio Be in 1 Year?
Motley Fool
Bluebird Bio
bb2121
Zynteglo
Flag link:
What Bluebird Bio Gets Wrong In Pricing For Its $1.8 Million Drug
What Bluebird Bio Gets Wrong In Pricing For Its $1.8 Million Drug
Forbes
Bluebird Bio
gene therapy
drug pricing
Zynteglo
beta thalassemia
Flag link:
Bluebird delays gene therapy launch to 2020, citing manufacturing tweaks
Bluebird delays gene therapy launch to 2020, citing manufacturing tweaks
Biopharma Dive
Bluebird Bio
gene therapy
drug manufacturing
Zynteglo
Flag link:
bluebird offers installment payments for Zynteglo gene therapy
bluebird offers installment payments for Zynteglo gene therapy
Pharmaforum
Bluebird Bio
outcome-based pricing
drug pricing
gene therapy
Zynteglo
beta thalassemia
Flag link:
Is $1.8 Million for bluebird bio's New Gene Therapy Ridiculous?
Is $1.8 Million for bluebird bio's New Gene Therapy Ridiculous?
Motley Fool
Bluebird Bio
Zynteglo
drug pricing
beta thalassemia
Flag link:
Bluebird sets $1.8M price tag for blood-disease gene therapy
Bluebird sets $1.8M price tag for blood-disease gene therapy
Biopharma Dive
drug pricing
Bluebird Bio
Zynteglo
Europe
beta thalassemia
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
Flag link:
Patients, payers await pricing plans for bluebird's first approved gene therapy
Patients, payers await pricing plans for bluebird's first approved gene therapy
BioCentury
Bluebird Bio
gene therapy
Zynteglo
drug pricing
beta thalassemia
Flag link:
Bluebird Bio’s Gene Therapy for Blood Disease Wins European Approval
Bluebird Bio’s Gene Therapy for Blood Disease Wins European Approval
Xconomy
Bluebird Bio
gene therapy
Europe
Zynteglo
EMA
beta thalassemia
Flag link:

Pages